Although an IFN response in cancer is contextual (22) and may trigger pro-or antitumorigenic responses, PRKN IFN signaling delivered potent anticancer activity, inhibiting transgenic and syngeneic tumor growth in vivo. The gene discussed is IFNA1; the disease is neoplasm.